Dendritic cells (DC) play a key role in initiating immune reactions after allogeneic stem cell transplantation. The two main peripheral blood DC populations are myeloid (DC1) and lymphoplasmacytoid (DC2). A new subset of myeloid DC, expressing CD16, has been identified. We analyzed the number and CD86 expression of DC subsets in peripheral blood of 18 healthy donors, before and after granulocyte colony-stimulating factor (G-CSF) and in the inoculum of allogeneic peripheral blood transplants (allo-PBT; n ¼ 100) and allogeneic bone marrow transplants (allo-BMT; n ¼ 22). Granulocyte colony-stimulating factor administration increased the median number of DC1 (P ¼ 0.0007), of DC2 (Po0.0001) and of DC CD16 þ (P ¼ 0.0001). Granulocyte colony-stimulating factor administration was also associated with a significant decrease of CD86 expression on DC1 (P ¼ 0.0003) and with a trend for an increase on DC CD16 þ (P ¼ 0.07). Recipients of allo-PBT received similar quantities of DC1 and higher doses of DC2 and DC CD16 þ than recipients of allo-BMT (P ¼ 0.5; P ¼ 0.0001; Po0.0001, respectively). Granulocyte colony-stimulating factor modifies the number of DC in peripheral blood and the expression of the costimulatory molecule CD86. This resulted in a different composition of DC2 and especially of DC CD16 þ in the harvests, which might explain some of the differences observed in allogeneic reactions after allo-PBT with respect to allo-BMT.
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Introduction
In Europe, more than 60% of allogeneic transplants are performed using peripheral blood as the source of progenitor cells (peripheral blood stem cell (PBSC)). 1 Clinical advantages of allogeneic peripheral blood transplants (allo-PBT) with respect to allogeneic bone marrow transplant (allo-BMT) include a less aggressive method for harvesting progenitor cells and more rapid neutrophil, platelet and lymphoid recovery after transplant. [2] [3] [4] [5] The incidence of acute graft-versus-host disease (GVHD) is very similar in both types of transplants, whereas chronic GVHD is more frequent after allo-PBT. [6] [7] [8] [9] [10] Differences in the cell composition of the bone marrow (BM) inoculum with respect to PBSC product are well known. [11] [12] [13] Several studies have shown that leukapheresis products from G-CSF-treated donors contain a much higher quantity of CD34 þ cells, monocytes, T-lymphocytes and natural killer (NK) cells than do bone marrow harvests. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] These differences may explain the higher incidence of chronic GVHD after allo-PBT, but the reason for a similar incidence of acute GVHD after both types of transplant, despite the higher amount of T cells infused with allo-PBT, remains uncertain. 14, 15 Dendritic cells (DC) are key for initiating immune responses as they are the only antigen-presenting cells that can prime naı¨ve T cells with a new antigen. [16] [17] [18] [19] DC play a critical role in the induction of acute GVHD. [20] [21] [22] [23] [24] DC populations are morphologically and phenotypically heterogeneous. They express high levels of major histocompatibility complex class II (HLA-DR þ þ ) and lack lineage-specific markers (CD3, CD14, CD19, CD56) (Lin À ). In humans, two distinct subsets of DC have been identified, based on their differential expression of CD33 and CD123, namely myeloid (DC1) and lymphoplasmacytoid (DC2), respectively. [25] [26] [27] [28] Recently, a new subset of DC that express CD16 (FcgRIII) and exhibits morphological and functional DC characteristics has been described in peripheral blood. [29] [30] DC CD16 þ display different morphological, cytochemical, immunophenotypical and functional characteristics compared to mature monocytes and the other DC. 30 Numeric differences in DC subsets between BM and peripheral blood inocula, and the effect of G-CSF on DC expression of costimulatory molecules, have not been fully analyzed. [31] [32] [33] [34] Moreover, a potential association of the number of DC administered with the incidence of acute and chronic GVHD after allo-PBT has not yet been studied. In the present study, we have analyzed the number and CD86 expression of DC1, DC2 and DC CD16 þ in peripheral blood of healthy donors before and after G-CSF administration. In addition, we have compared the number and characteristics of DC administered to recipients of allo-PBT as compared to allo-BMT.
Materials and methods

Cell samples
Bone marrow hematopoietic stem cells were harvested (n ¼ 22) from healthy donors for allogeneic transplant from posterior iliac crests under general anesthesia, according to standard institutional procedures. The target dose was 3 Â 10 6 CD34 þ cells/kg of recipient weight, with a maximum marrow volume of 20 ml/kg donor weight. Healthy donors of PBSC for allogeneic transplants (n ¼ 100) received G-CSF (filgrastim) at a dose of 10 mg/ kg per day subcutaneously for 5 days. Peripheral blood samples from 18 of them were obtained the day before starting G-CSF treatment and 30 min before leukapheresis. Peripheral blood stem cells were collected by leukapheresis starting on day 5 to achieve a target dose of 4 Â 10 6 CD34 þ cells/kg of recipient weight. A sample from the BM harvest and leukapheresis product was obtained before infusion to patients. All samples were collected in tubes containing ethylene-diaminetetracetic acid (EDTA). A routine blood count was performed using an automated hematology analyzer. Samples were collected from five Spanish hemopoietic transplant units. All cell counts and immunophenotypic analyses were performed, with less than 36 h of delay, in a single center (Hospital Clı´nic, Barcelona, Spain). This study was approved by the local Ethics Committee and by the Spanish Health Department. Informed consent was obtained from all patients.
Monoclonal antibodies
Monoclonal antibodies (mAbs) used for analyzing DC were conjugated with different fluorochromes: fluorescein isothiocyanate (FITC) for mAbs specific for lineage (anti-Lin) such as CD3, CD14, CD19, and CD56; phycoerythrin (PE) for CD123, CD16 and CD86; peridin chlorophyll protein (PerCP) for anti-HLA-DR; and allophycocyanin (APC) for CD33. Monoclonal antibodies used for analyzing the number of CD34 þ cells, T-lymphocytes, NK cells and monocytes administered to the patients were: anti-CD45 FITC and anti-CD34 PE for the quantification of CD34 þ cells; anti-CD8 FITC, anti-CD4 PE, anti-CD3 PerCPCy5.5 and anti-CD45 APC for the quantification of Tlymphocytes; anti-CD3 FITC, anti-CD16 þ CD56 PE and anti-CD45 PerCP-Cy5.5 for NK cells; and anti-CD14 FITC and anti-CD45 PE for monocytes. Monoclonal antibodies were purchased from Becton Dickinson (BD, San Jose, CA, USA).
Flow cytometric cell enumeration
Flow cytometric analysis was performed on fresh samples of peripheral blood and harvest products. For analyzing DC, 150 ml of blood or marrow samples were used for immunofluorescence staining. Samples from leukapheresis products and from peripheral blood after G-CSF treatment were diluted 1:10 with sterile phosphate-buffered saline (PBS). MAbs were added to the cell samples and followed by 15 min incubation at room temperature. In nine donors in whom two aphereses were performed, DCs were quantified in both apheresis products and the average result was used for the analysis. Red cells were lysed using 3 ml of FACS lysing solution (BD), incubated at room temperature during 30 min, washed by centrifuging and resuspended in 0.5 ml of FACS lysing solution. The samples were acquired on a FACSCalibur flow cytometer (BD) with four-color analysis, using Cellquest software (BD). The instrument setting was established first and compensation was adjusted by acquiring cells stained with each fluorochrome-conjugated mAbs. A total of 150 000 events was collected from each tube. For data analysis, Paint-a-Gate s software was used. For analyzing the number of CD34 cells, T-lymphocytes, NK cells and monocytes, 50 ml of leukapheresis product or marrow sample were used. A total of 50 000 events was collected from each tubes using Cellquest software (BD) and analyzed by Paint-a-Gate s software. CD86 expressions on DC1 and DC CD16 þ before and after G-CSF were analyzed with CD86 PE using Cellquest software.
Statistical analysis
Differences in continuous variables were analyzed with Student's t-test for dependent samples. The Mann-Whitney U-test was used for variables not following a normal distribution. Statistical studies were performed by means of SPSS 6.1 (1994) or Statistica 5.1 (1997) statistical software.
Results
Identification of dendritic cell subsets
Dendritic cells, identified as positive for HLA-DR and negative for CD3, CD19, CD14 and CD56 lineage markers (Figure 1a) , constituted on average 1% of total cells in the peripheral blood of healthy donors before G-CSF treatment. They were larger and more granular than lymphocytes, but smaller and less granular than monocytes (Figure 1b) . Dendritic cells were classified based on their expression of CD33 for DC1, CD123 (IL-3 receptor a-chain) for DC2, and CD16 (FcgRIII) for DC CD16 þ (Figure 1c and 1d) . The expression of these molecular markers was not modified with the administration of G-CSF, and was similar in peripheral blood and BM cells (data not shown). The absolute number of DC subpopulations in the sample was calculated considering the white blood cell count, multiplied by the proportion of each subpopulation as determined by flow cytometric analysis.
Dendritic cell numbers in peripheral blood before and after granulocyte colony-stimulating factor administration In healthy donors, mean white blood cells in peripheral blood before and after 5 days of G-CSF was 6.8 Â (Figure 2 ). The proportion of donors in which the number of DC1, DC2 and DC CD16 þ increased after G-CSF was of 88, 94 and 94%, respectively.
CD86 expression in dendritic cells before and after granulocyte colony-stimulating factor
The expression of the costimulatory molecule CD86 was calculated in DC1 and DC CD16 þ subsets, before (n ¼ 10) and after (n ¼ 26) G-CSF treatment. We identified these two myeloid DC populations based on their different expression of CD33. On DC1, CD86 expression significantly decreased after 5 days of G-CSF administration in healthy donors has a potent effect on mobilizing DC2 and DC CD16 þ subsets. Analysis of peripheral blood samples before and after G-CSF administration in 18 healthy donors in DC CD16 þ . Dendritic cell subsets were identified as described in 'Materials and methods'. Each symbol represents a single sample. Horizontal lines in each series represent median values. P-values were determined using t-test for dependent samples.
(P ¼ 0.0003). In contrast, there was a trend towards an increase in CD86 expression in DC CD16 þ subset after G-CSF administration (P ¼ 0.07) (Figure 3 ).
Dendritic cell subsets in leukoapheresis product and in bone marrow harvest We did not observe any difference in the number of DC1 contained in PBSC grafts (n ¼ 100) as compared to BM grafts (n ¼ (Figure 4 ). The number of CD4 þ , CD8 þ , monocytes and NK cells infused is shown in Table 1 .
Discussion
We have observed significant differences in the DC content between PBSC and BM harvests intended for allogeneic transplantation. Although the number of DC1 was very CD16 PE Figure 4 Recipients of allogeneic peripheral blood transplant (allo-PBT) received higher doses of DC2 and DC CD16 þ than recipients of allogeneic bone marrow transplant (allo-BMT). The study was realized in leukapheresis products (n ¼ 100) and bone marrow harvests (n ¼ 22).
G-CSF modifies DC CD16 þ and the expression of CD86 C Talarn et al similar in PBSC and in BM inocula, the number of DC2 and of DC CD16 þ was much higher in PBSC (Figure 2 ). Arpinati et al. 31 have also recently shown that PBSC contain similar numbers of DC1 and more DC2 than marrow harvests Both populations have different functional roles. DC2 has less potential than DC1 to activate proliferation of naı¨ve allogeneic T cells, and it has been associated with a decreased potential to induce acute GVHD. 35 We have observed that PBSC contained not only more DC2 but also 40 times more DC CD16 þ in comparison to marrow harvests, a finding not reported previously. DC CD16 þ is a potent allostimulatory cell, which comprises a large proportion of myeloid blood DC, expresses low levels of CD14 and CD33, and is the only subset to lack cutaneous lymphocyte antigen (CLA) expression. 29, 30 This particular DC subset is raising great interest owing to its important role against tumors 36, 37 and infections. 38, 39 The higher quantity of DC2 and DC CD16 in the leukapheresis as compared to BM product may be explained by the fact that G-CSF not only mobilizes CD34 þ cells, monocytes and neutrophils to peripheral blood but also has a potent effect on mobilizing DC2 and DC CD16 þ subsets. Indeed, an increase in the number of DC2 in peripheral blood after G-CSF administration has been reported, [31] [32] [33] and this effect has been attributed to the induction of the physiological migration of DC2 from the marrow, through the blood, into peripheral lymphoid organs. 31, 33 In our study, the most striking effect was the dramatic increase in the number of DC CD16 þ in peripheral blood after G-CSF administration (Figure 2) .
It has been suggested that G-CSF might modify the characteristics and function of DC, 40 but to the best of our knowledge, there are no reports about the effect of G-CSF on the expression of costimulatory molecules on DC. CD86, costimulatory molecule member of the B7-CD28 family, is crucial in regulating the activation of naı¨ve T cells. Full activation of T cells requires two signaling events, one through the antigen-specific receptor (TCR) and one through the receptor for a costimulatory molecule, B7-1 (CD80) or B7-2 (CD86). In the absence of the latter signal, T cells do not produce appreciable amounts of cytokines and become unresponsive to stimulation or undergo apoptosis. 41, 42 We investigated CD86 expression on DC1 and DC CD16 þ subsets from peripheral blood before and after G-CSF administration. Our findings show, for first time, a different effect of G-CSF on CD86 expression of DC1 and DC CD16 þ . Thus, while CD86 expression decreased on DC1 after 5 days of G-CSF administration, there was a trend for an increase in the DC CD16 þ population (Figure 3 ). The importance of CD86 costimulatory expression on DC surface for optimal T-cell activation was first described by Azuma et al. 43 Later, several groups showed that mAb CD86 blocked naı¨ve T-cell activation and that this resulted in a lower induction of acute GVHD. [44] [45] [46] [47] [48] Of note, it has been reported that pretreatment of donor mice with G-CSF reduced the incidence and severity of GVHD. 35, 49 This has been attributed to the shift from Th1 to Th2. However, downregulation of CD86 in DC1 induced by G-CSF, as observed in our study, might also play a role.
In conclusion, this study shows that G-CSF administration induces important changes in the number of DC subsets and on their expression of costimulatory molecule CD86. This resulted in a different composition of DC2 and especially of DC CD16 þ in the harvests. The relationship between these findings and their clinical relevance in the evolution of the allogeneic transplant should be further investigated. 
